- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Dusigitumab is an investigational monoclonal antibody which neutralises circulating insulin-like growth factor (IGF)-I and IGF-2. These growth factors regulate cell growth, survival, differentiation, and transformation. Antibody-mediated ligand neutralisation prevents these growth hormones from activating signalling via both IGF1R and IR-A (insulin receptor isoform A, Uniprot identifier P06213-2, RefSeq protein NP_001073285).
Peptide sequence alignment suggests that dusigitumab is antibody 7-159-1 in patent US7939637 .
|No information available.|
|Summary of Clinical Use|
|Dusigitumab (research code MEDI-573) is being assessed in clinical trials as a treatment for advanced/metastatic solid tumours , including unresectable/metastatic hepatocellular carcinoma (HCC) and HER-2 negative metastatic breast cancer. Click here to link to ClinicalTrials.gov's list of MEDI-573 registered trials.|